Outlook Therapeutics, Inc. (OTLK)
What's happening with OTLK?
Powered by Yahoo ScoutOutlook Therapeutics is gearing up for the U.S. launch of LYTENAVA, its FDA-approved treatment for wet AMD, with new CFO Kevin Lundquist appointed to oversee financial strategies. However, concerns linger regarding the company's weak balance sheet and past stock performance, which has seen a 98% declineover five years.
- Previous Close
0.6490 - Open
0.6599 - Bid 0.4835 x 200
- Ask 0.6763 x 100
- Day's Range
0.6451 - 0.6962 - 52 Week Range
0.1610 - 2.5380 - Volume
6,354,446 - Avg. Volume
17,749,816 - Market Cap (intraday)
161.741M - Beta (5Y Monthly) 0.75
- PE Ratio (TTM)
-- - EPS (TTM)
-0.7000 - Earnings Date Aug 14, 2026
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
4.90
Recent News
View MorePerformance Overview
Trailing total returns as of 9/4/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Earnings Trends
View MoreAnalyst Insights
View MoreStatistics
View MoreValuation Measures
-
Market Cap
-
Enterprise Value
-
Trailing P/E
-
Forward P/E
-
PEG Ratio (5yr expected)
-
Price/Sales (ttm)
-
Price/Book (mrq)
-
Enterprise Value/Revenue
-
Enterprise Value/EBITDA
Financial Highlights
Profitability and Income Statement
-
Profit Margin
0.00%
-
Return on Assets (ttm)
-143.17%
-
Return on Equity (ttm)
--
-
Revenue (ttm)
-1.16M
-
Net Income Avi to Common (ttm)
-61.12M
-
Diluted EPS (ttm)
-0.7000
Balance Sheet and Cash Flow
-
Total Cash (mrq)
11.24M
-
Total Debt/Equity (mrq)
--
-
Levered Free Cash Flow (ttm)
-37.36M
Compare
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
